NovaTears, AFT Pharmaceuticals’ new preservative-free eye lubricant and tear film stabiliser for the treatment of Evaporative Dry Eye (EDE), has been listed on the PBS from 1 September 2018.
Research has shown that EDE is by far the most common type of Dry Eye Disease (DED), impacting approximately 86 per cent of DED sufferers (50 per cent experience EDE alone and a further 36 per cent experience a combination of EDE and aqueous deficiency).1
NovaTears… has been listed on the PBS from 1 September 2018
NovaTears is a new class of dry eye therapy based on patented EyeSol technology, which can provide relief for EDE sufferers, and fulfil a significant patient need,” explained Dr. Hartley Atkinson, pharmacologist and CEO of AFT Pharmaceuticals. “It’s long-lasting and spreads very easily across the eye, providing relief without blurred vision, stinging or burning.”
Being water-free is one of the major benefits of NovaTears, as it means there is no microbial growth possible in the solution and allows for the delivery of preservative-free drops in a convenient multi-dose bottle. NovaTears droplets are also four to five times smaller than traditional water-based eye drops, which minimises spill-over.
“Clinical studies of evaporative dry eye disease and meibomian gland dysfunction patients have shown significant improvement in objective signs and subjective symptoms after using NovaTears,”2 said Dr. Atkinson. “We are very pleased to see NovaTears listed on the PBS, allowing greater access to EDE sufferers, particularly those who are sensitive to preservatives.”
References:
1. Lemp, M.A., Crews, L.A., Bron, A.J., Foulks, G.N. and Sullivan, B.D., 2012. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea, 31(5), pp.472-478.
2. Steven, Philipp, et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease – A Prospective, Multicenter Noninterventional Study.” Journal of Ocular Pharmacology and Therapeutics 31 (8), 498-503(2015) and Steven, Philipp, et al. “Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease.” Journal of Ocular Pharmacology and Therapeutics. 33(9), 678-685(2017).Sponsored by Novaliq GmbH.
